List of adverse effects of imatinib

This is a list of adverse effects of the anti-cancer drug imatinib, sorted by frequency of occurrence.[1][2][3][4][5]

Very common

Very common (>10% incidence) adverse effects include:

  • Myelosuppression (see below for details)
  • Headache
  • Nausea
  • Vomiting
  • Diarrhoea
  • Oedema
  • Abdominal pain
  • Dyspepsia (indigestion)
  • Periorbital oedema
  • Dermatitis
  • Eczema
  • Rash
  • Muscle spasms or cramps
  • Muscle aches
  • Joint pain
  • Bone pain
  • Fatigue
  • Weight gain

Common

Common (1–10% incidence) adverse effects include:

  • Weight loss
  • Insomnia
  • Dizziness
  • Paraesthesias
  • Taste disturbance
  • Hypoaesthesia
  • Lacrimination
  • Conjunctivitis
  • Dry eye
  • Blurred vision
  • Flushing
  • Haemorrhage
  • Dyspnoea
  • Epistaxis (nosebleeds)
  • Cough
  • Flatulence
  • Abdominal distension
  • Gastro-oesophageal reflux
  • Constipation
  • Dry mouth
  • Gastritis
  • Increased hepatic enzymes
  • Itchiness
  • Dry skin
  • Erythema
  • Alopecia (hair loss)
  • Night sweats
  • Photosensitivity reaction
  • Joint swelling
  • Weakness
  • Fever without an infectious cause
  • Anasarca
  • Chills
  • Rigors

Uncommon

Uncommon (0.1–1% incidence) adverse effects include:

  • Herpes zoster
  • Herpes simplex
  • Nasopharyngitis
  • Pneumonia
  • Sinusitis
  • Cellulitis
  • Upper respiratory tract infection
  • Influenza
  • Urinary tract infection
  • Gastroenteritis
  • Sepsis
  • Hypokalaemia
  • Increased appetite
  • Hypophosphataemia
  • Decreased appetite
  • Dehydration
  • Gout
  • Hyperuricaemia
  • Hypercalcaemia
  • Hyperglycaemia
  • Hyponatraemia
  • Depression
  • Libido decreased
  • Anxiety
  • Migraine
  • Somnolence
  • Syncope
  • Peripheral neuropathy
  • Memory impairment
  • Sciatica
  • Restless leg syndrome
  • Tremor
  • Cerebral haemorrhage
  • Eye irritation
  • Eye pain
  • Orbital oedema
  • Scleral haemorrhage
  • Retinal haemorrhage
  • Blepharitis
  • Macular oedema
  • Vertigo
  • Tinnitus
  • Hearing loss
  • Palpitations
  • Tachycardia
  • Congestive heart failure
  • Pulmonary oedema
  • Hypertension
  • Haematoma
  • Subdural haematoma
  • Peripheral coldness
  • Hypotension
  • Raynaud's phenomenon
  • Pleural effusion
  • Pharyngolaryngeal pain
  • Pharyngitis
  • Stomatitis
  • Mouth ulceration
  • Gastrointestinal haemorrhage
  • Eructation
  • Melaena
  • Oesophagitis
  • Ascites
  • Gastric ulcer
  • Haematemesis
  • Cheilitis
  • Dysphagia
  • Pancreatitis
  • Hyperbilirubinaemia
  • Hepatitis
  • Jaundice
  • Pustutular rash
  • Contusion
  • Increased sweating
  • Urticaria
  • Ecchymosis
  • Increased tendency to bruise
  • Hypotrichosis
  • Skin hypopigmentation
  • Dermatitis exfoliative
  • Onychoclasis
  • Folliculitis
  • Petechiae
  • Psoriasis
  • Purpura
  • Skin hyperpigmentation
  • Bullous eruptions
  • Joint and/or muscle stiffness
  • Renal pain
  • Haematuria
  • Renal failure
  • Increased urinary frequency
  • Gynaecomastia
  • Erectile dysfunction
  • Menorrhagia
  • Irregular menstruation
  • Sexual dysfunction
  • Nipple pain
  • Breast enlargement
  • Scrotal oedema
  • Chest pain
  • Malaise
  • Blood creatinine increased
  • Blood creatine phosphokinase increased
  • Blood lactate dehydrogenase increased
  • Blood alkaline phosphatase increased

Myelosuppression more commonly occurs in CML patients and includes: thrombocytopenia and neutropenia.[5] Thrombocytopenia usually lasts for 2–3 weeks and neutropenia for 3–4 weeks.[5]

References

  1. "Gleevec (imatinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 24 January 2014.
  2. "GLEEVEC (imatinib mesylate) tablet [Novartis Pharmaceuticals Corporation]". DailyMed. Novartis Pharmaceuticals Corporation. October 2013. Retrieved 24 January 2014.
  3. "GLIVEC Tablets - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Novartis Pharmaceuticals UK Ltd.
  4. "GLIVEC (imatinib)" (PDF). TGA eBusiness Services. Novartis Pharmaceuticals Australia Pty Ltd. 21 August 2013. Retrieved 24 January 2014.
  5. 1 2 3 Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
This article is issued from Wikipedia - version of the Sunday, July 19, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.